Immix Biopharma, Inc.

As of June 20, 2025, Immix Biopharma, Inc. shows a mildly bullish trend in the short term, supported by daily and weekly indicators, but longer-term signals indicate caution due to a bearish monthly MACD and mixed Bollinger Bands.

Immix Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $63.56 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of -217.96%.

As of Jun 18, Immix Biopharma, Inc. has a market capitalization of 63.56 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -20.91 million over the last four quarters. The company reported shareholder's funds of 13.25 million and total assets of 22.95 million as of Dec 24.